EGFR Mutation and Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers in Lung Adenocarcinoma: Insights from Western India
DOI:
https://doi.org/10.21276/apalm.3654Keywords:
Lung adenocarcinoma, EGFR mutation, NLR, progression-free survival, histopathology, systemic inflammationAbstract
Background: Lung adenocarcinoma is a heterogeneous malignancy where epidermal growth factor receptor (EGFR) mutations and systemic inflammation markers like neutrophil-to-lymphocyte ratio (NLR) serve as crucial prognostic tools. Our objective is to analyze the prevalence and types of EGFR mutations, correlation with addiction and histomorphological patterns, and evaluate the prognostic impact of NLR on progression-free survival (PFS) and overall survival (OS).
Methods: This observational study was conducted at a tertiary care center in Gujarat, including 317 cases of lung adenocarcinoma from 2018-2024. EGFR mutation testing was performed on 113 cases using PCR and pyrosequencing. NLR was derived from baseline blood counts and categorized using Youden's index-derived ROC cut-off (2.89). Kaplan-Meier survival analysis and Cox regression were employed to assess outcomes.
Result: EGFR mutations were detected in 36/113 cases (31.8%), more frequently in females (53%) than males (23%). Exon 19 deletions were the most common (66.7%). A significant association was found between EGFR mutation and non-addiction status (p=0.019). Glandular histology predominated among both mutated (58.3%) and wild-type (80.5%) cases. High-NLR status (≥2.89) was significantly associated with shorter PFS (median ≈10 vs ≈19 months, HR 1.44, p=0.23). OS was shorter in high-NLR cases (median ≈11 vs ≈24 months, HR 1.51, p=0.18).
Conclusion: EGFR mutations are more prevalent in non-smoking females and are associated with specific histological subtypes. Elevated NLR is a strong predictor of poor PFS, reinforcing its utility as a prognostic biomarker in lung adenocarcinoma. Integrating EGFR and NLR status into diagnostic protocols can enhance individualized management strategies.
References
1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci US A. 2004; 101(36):13306-13311.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
5. Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan Arch Toxicol DOI 10.1007/s00204-015-1524-7
6. Mantovani A, Allavena P, Sica A, Balkwill F: Cancerrelated inflammation. Nature 2008; 454: 436-444.
7. Hanahan D. Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
8. Jafri SH, Shi R, Mills G: Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013; 13: 158.
9. Templeton AJ, McNamara MG, Seruga B, et al.: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.
10. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC: The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep 2017; 7: 16717.
11. Yin Y, Wang J, Wang X, et al.: Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics (Sao Paulo) 2015; 70: 524-530.
12. Berardi R, Rinaldi S, Santoni M, et al.: Prognostic models to predict survival in patients with advanced nonsmall cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 2016; 7: 26916-26924.
13. YuY, Qian L, Cui J: Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a metaanalysis of 7,219 patients. Mol Clin Oncol 2017; 7: 498-506
14. Yoshizawa A, Sumiyoshi S. Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52-61.
15. Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013;8(4):461-468.
16. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013;30(3):645.
17. Yoshida T, Ishii G, Goto K, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol. 2013;139(10):1691-1700.
18. Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, et al. Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med. 2018 Feb 142(2):183-90.
19. Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T. Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct;19(10):1438-1448.
20. Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, DeCamp MM, Raparia K. Correlation of EGFR Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med. 2014 Oct;138(10):1353-7.
21. Aguiar-Bujanda D, Dueñas-Comino A, Saura-Grau S, Ros-Sanjuan L, Blanco-Sanchez MJ, Hernandez-Sosa M, Mori-De Santiago M, Galvan-Ruiz S, Lorenzo-Barreto JE, Vargas-Prado AM, Bohn-Sarmiento U. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. Oncol Res Treat. 2018 41(12):755-760.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Shyama Manojkumar Chag, Khevna Mayurkumar Kansara, Monica Vikas Gupta, Nirav Niranjanbhai Asarawala
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
